Clinical trial Recruiting at 1 site Observational Ages 18 and up

Predictors of Major Adverse Limb Events After Iliac Artery Stenting

Official title: Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort Study (PREMISE-ILIAC Study)

Run by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · NCT07672249 · Data updated 2026-11-12

This study tests what factors predict serious limb-related problems after iliac artery stenting in adults with peripheral artery disease.

More Peripheral Arterial Disease trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment98 (estimated)
SponsorI.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Academic / other
Locations1 site (Milan, Mi)
StatusRecruiting
StartedJune 16, 2026
Main results expectedJuly 1, 2026
Study endsJuly 16, 2026
Registry record updatedJune 30, 2026
Trial IDNCT07672249 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 and older with symptomatic peripheral arterial disease involving the iliac arteries who are treated with endovascular iliac artery stenting at the participating center.

Probably not a fit

Patients with non-iliac targets, prior iliac stenting, or those undergoing open surgical revascularization are not the focus of this analysis and may not benefit from study findings relevant to iliac stenting outcomes.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective, single-center observational study of adults undergoing endovascular iliac artery stenting. It aims to identify patient- and lesion-related factors that predict Major Adverse Limb Events in a real-world population with substantial comorbidity. Outcomes will include limb-related adverse events after the procedure and will be analyzed in relation to baseline characteristics and imaging findings. The study uses data from routine clinical care at a high-volume Italian center to generate insights applicable to everyday practice. No interventional assignment is made; the focus is on observational associations in real-world care.

Why it matters

Potential benefit: Insights from this study could help clinicians better identify patients at higher risk for MALE after iliac stenting and tailor follow-up and management accordingly.

How similar studies have gone: Previous work has explored predictors of limb events in endovascular populations, but real-world, unselected cohorts for iliac stenting remain limited, making this study relatively novel in its scope.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Adult patients aged ≥18 years, of both male and female sex

* Presence of haemodynamically significant stenosis or occlusion of the common iliac artery (CIA) and/or external iliac artery (EIA), documented by computed tomography angiography, magnetic resonance angiography, or diagnostic angiography
* Symptomatic peripheral artery disease, including lifestyle-limiting intermittent claudication (Rutherford category 2-3) or chronic limb- threatening ischaemia (CLTI; Rutherford category 4-6), refractory to optimal medical therapy
* Treatment with endovascular iliac artery stenting (covered or uncovered; balloon-expandable or self-expanding devices) as the primary revascularisation strategy
* De novo iliac lesions only
* Availability of complet

Exclusion Criteria:

Primary open surgical revascularisation of the iliac axis (e.g., aorto- bifemoral bypass or endarterectomy).

* Previous stenting of the target iliac segment (in-stent restenosis cases excluded).
* Aorto-iliac aneurysmal disease as the primary indication for treatment (including EVAR or fenestrated endografts).
* Hybrid procedures with concomitant infrainguinal bypass surgery.
* Incomplete clinical, procedural, or follow-up data preventing assessment of study endpoints.
* Loss to follow-up without documented clinical outcomes.

Where it's running

  • IRCCS Galeazzi Sant'Ambrogio Hospital
    Milan, Mi, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.